Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2013

Planlagt Fastgjort Låst Flyttet Genmab
226 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #197

    Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

    favicon

    (www.fiercebiotech.com)

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #198

      Indimellem er det lidt trættende at Arzerra aldrig nævnes 😞

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #199

        Det skal ASH rode bod på !!

        1 Reply Last reply
        0
        • 1 Offline
          1 Offline
          120281
          wrote on sidst redigeret af
          #200

          De bliver klogere

          1 Reply Last reply
          0
          • JørgenVarnæsJ Offline
            JørgenVarnæsJ Offline
            JørgenVarnæs
            wrote on sidst redigeret af
            #201

            er HSBC's opkøbsforsøg gået i sig selv igen?

            1 Reply Last reply
            0
            • investor1989I Offline
              investor1989I Offline
              investor1989
              wrote on sidst redigeret af
              #202

              Just a moment...

              favicon

              (www.proinvestor.com)

              1 Reply Last reply
              0
              • S Offline
                S Offline
                stoft
                wrote on sidst redigeret af
                #203

                Det blir dejlig af være genmab aktionær idag 🙂

                1 Reply Last reply
                0
                • JørgenVarnæsJ Offline
                  JørgenVarnæsJ Offline
                  JørgenVarnæs
                  wrote on sidst redigeret af
                  #204

                  Der bliver varmet om til ASH og det store showdown i CLL markedet - her er lidt baggrund på de forskellige spillere: http://seekingalpha.com/article/1860201-gilead-vs-johnson-johnson-roche-in-blood-cancer-showdown?source=yahoo

                  1 Reply Last reply
                  0
                  • MadsSkjernM Offline
                    MadsSkjernM Offline
                    MadsSkjern
                    wrote on sidst redigeret af
                    #205

                    CLL, competitive landscape. Arzerra er godt med i kombi med ibrutinib og idelalisib https://twitter.com/zDonShimoda/status/405007
                    519640064000/photo/1/large

                    1 Reply Last reply
                    0
                    • MadsSkjernM Offline
                      MadsSkjernM Offline
                      MadsSkjern
                      wrote on sidst redigeret af
                      #206

                      https://twitter.com/zDonShimoda/status/405007519640064000/photo/1/large

                      1 Reply Last reply
                      0
                      • JørgenVarnæsJ Offline
                        JørgenVarnæsJ Offline
                        JørgenVarnæs
                        wrote on sidst redigeret af
                        #207

                        ja, det bliver lidt af et landskab at fylde ud. Arzerra + alkylator er ikke taget med i opgørelsen.

                        1 Reply Last reply
                        0
                        • investor1989I Offline
                          investor1989I Offline
                          investor1989
                          wrote on sidst redigeret af
                          #208

                          "
                          This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)."

                          1 Reply Last reply
                          0
                          • investor1989I Offline
                            investor1989I Offline
                            investor1989
                            wrote on sidst redigeret af
                            #209

                            Var faktisk ikke klar over at vi fik sådanne data

                            1 Reply Last reply
                            0
                            • investor1989I Offline
                              investor1989I Offline
                              investor1989
                              wrote on sidst redigeret af
                              #210

                              Gazyva comes with a boxed warning about the possibility that the Hepatitis B virus could reactivate and it could cause PML (progressive multifocal leukoencephalopathy). PML is a rare brain disorder that damages the material which protects the nerves in the brain.

                              1 Reply Last reply
                              0
                              • investor1989I Offline
                                investor1989I Offline
                                investor1989
                                wrote on sidst redigeret af
                                #211

                                lyder hyggeligt 🙂

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #212

                                  BendOfa refractory CLL: The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% CI, 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months.

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #213

                                    BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high risk clinical and biological features.

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #214

                                      accepted article preview 13 November 2013; doi: 10.1038/leu.2013.334 http://www.nature.com/leu/journal/vaop/naam/abs/leu2013334a.html

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #215

                                        Ja - arzerra er ikke helt uden virkning

                                        1 Reply Last reply
                                        0
                                        • celsiusC Offline
                                          celsiusC Offline
                                          celsius
                                          wrote on sidst redigeret af
                                          #216

                                          Gentogen: og så på dansk -:)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger